2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
Sex differences in peripheral artery disease
Peripheral artery disease (PAD) is a prevalent condition that confers substantial morbidity
and mortality and remains underdiagnosed as well as undertreated in the overall …
and mortality and remains underdiagnosed as well as undertreated in the overall …
Pathophysiology of peripheral arterial disease in diabetes mellitus: 糖尿病周围动脉疾病的病理生理机制
S Yang, L Zhu, R Han, L Sun, J Li, J Dou - Journal of diabetes, 2017 - Wiley Online Library
Peripheral arterial disease (PAD) increases the risk of lower extremity amputation. It is also
an independent predictor of cardiovascular and cerebrovascular ischemic events, affecting …
an independent predictor of cardiovascular and cerebrovascular ischemic events, affecting …
[HTML][HTML] Global vascular guidelines on the management of chronic limb-threatening ischemia
Guideline Summary Chronic limb-threatening ischemia (CLTI) is associated with mortality,
amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are …
amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are …
[PDF][PDF] 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
W 2011 roku ESC opublikowało pierwsze wytyczne dotyczące rozpoznawania i leczenia
chorób tętnic obwodowych (PAD)[1]. Ta publikacja wypełniła ważną lukę wśród wytycznych …
chorób tętnic obwodowych (PAD)[1]. Ta publikacja wypełniła ważną lukę wśród wytycznych …
Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further …
MP Bonaca, P Nault, RP Giugliano, AC Keech… - Circulation, 2018 - Am Heart Assoc
Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor
evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the …
evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the …
2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American …
MD Gerhard-Herman, HL Gornik, C Barrett… - Journal of the American …, 2017 - jacc.org
The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …
initial extensive evidence review, which included literature derived from research involving …
[HTML][HTML] Editor's Choice–2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular …
Document Reviewers b, Petr Widimsky, Philippe Kolh, Stefan Agewall, Héctor Bueno,
Antonio Coca, Gert J. De Borst, Victoria Delgado, Florian Dick, Cetin Erol, Marc Ferrini …
Antonio Coca, Gert J. De Borst, Victoria Delgado, Florian Dick, Cetin Erol, Marc Ferrini …
[PDF][PDF] 2016 European Guidelines on cardiovascular disease prevention in clinical practice
MF Piepoli, AW Hoes, S Agewall… - Polish Heart …, 2016 - journals.viamedica.pl
2.3. 9. Wnioski................................................ 838 2.4. Inne markery ryzyka.......................................
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias
AL Catapano, I Graham, G De Backer… - Polish Heart …, 2016 - journals.viamedica.pl
5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …